Business
Cannabics Pharmaceuticals Announces Start of Clinical Study in Israel for Cancer Patients
Cannabics Pharmaceuticals Announces Start of Clinical Study in Israel for Cancer Patients.
About this update from Cnbx Pharmaceuticals Inc.
[{"type":"text","content":"\n\n\n\nCannabics Pharmaceuticals Announces Start of Clinical Study in Israel for Cancer Patients\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\nCannabics Pharmaceuticals Announces Start of Clinical Study in Israel for Cancer Patients\nPR Newswire\nBETHESDA, Maryland, March 22, 2016\n\n\n\n\n\n\n\n\nBETHESDA, Maryland, March 22, 2016 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (CNBX) today announced the start of a clinical study in Israel for cancer patients utilizing Cannabics' SR Capsules. This is one of the world's first clinical studies specifically examining the effect of cannabis utilizing a medically standardized edible delivery system.\n\n\nThis clinical study involves patients with advanced cancer and cancer anorexia cachexia syndrome (CACS), endpoints examined are weight gain appetite, quality of life and a marker for anti-cancer activity. Quality of life in patients with CACS is directly related to loss of appetite and loss of weight. This study examines the influence of Cannabics Pharmaceuticals SR capsules on both of these common effects of cancer and cancer treatment.\n\nSecondary outcome measures are improvement in appetite, reduction in TNF-alpha level, safety assessment for early psychiatric side-effects, quality of life and evaluation of muscle strength.\n\nThese studies are being carried out by the prestigious Rambam Medical Center in northern Israel and under strict regulations of the Ministry of Health, by whom Cannabics Pharmaceuticals has been licensed since 2014. \n\nSaid Dr. Eyal Ballan, CTO of the Company, \"We expect the clinical proof of safety and efficacy to be of imperative importance to the medical community and particularly to prescribing physicians. We anticipate that successful completion of these clinical studies utilizing Cannabics SR capsules will further scientifically legitimize the use of this standardized delivery mechanism in the eyes of the medical community.\"\n\nCannabics SR is an extended release oil capsule that provides a safe, effective and reliable administration of medical grade cannabis. It is composed solely ...